SAN DIEGO – Resmed says that U.S. Customs and Border Protection has confirmed that its devices will continue to be exempt from tariffs and, therefore, the company does not expect a material impact on ...

Resmed produces sleep apnoea machines and accompanying technology in Singapore and Australia, and the $49bn company confirmed this week its existing tariff exemption will continue in the US.

Don't miss out on the headlines from Companies. Followed categories will be added to My News. ResMed CEO Mick Farrell on Thursday revealed the Trump administration will not apply tariffs to goods ...

Followed categories will be added to My News. Resmed produces sleep apnoea machines and accompanying technology in Singapore and Australia, and the $49bn company confirmed this week its existing ...

The CEO of ResMed, a $49b company which manufactures sleep devices to treat sleep apnea and other chronic respiratory conditions, on Thursday revealed the Trump Administration will not apply ...

Recently, ResMed reported solid financial performance for the quarter ending March 31, 2025, with sales increasing to $1,292 million and net income reaching $365 million year-over-year.